Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
-
Published:2021-06-26
Issue:1
Volume:189
Page:187-202
-
ISSN:0167-6806
-
Container-title:Breast Cancer Research and Treatment
-
language:en
-
Short-container-title:Breast Cancer Res Treat
Author:
Ademuyiwa Foluso O.ORCID, Chen Ina, Luo Jingqin, Rimawi Mothaffar F., Hagemann Ian S., Fisk Bryan, Jeffers Gejae, Skidmore Zachary L., Basu Anamika, Richters Megan, Ma Cynthia X., Weilbaecher Katherine, Davis Jennifer, Suresh Rama, Peterson Lindsay L., Bose Ron, Bagegni Nusayba, Rigden Caron E., Frith Ashley, Rearden Timothy P., Hernandez-Aya Leonel F., Roshal Anna, Clifton Katherine, Opyrchal Mateusz, Akintola-Ogunremi Olaronke, Lee Byung Ha, Ferrando-Martinez Sara, Church Sarah E., Anurag Meenakshi, Ellis Matthew J., Gao Feng, Gillanders William, Griffith Obi L., Griffith Malachi
Funder
National Cancer Institute NeoImmnuneTech Cancer Prevention and Research Institute of Texas National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference62 articles.
1. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL (2019) Breast cancer statistics. CA Cancer J Clin 69(6):438–451. https://doi.org/10.3322/caac.21583 2. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159. https://doi.org/10.1056/NEJMoa1612645 3. Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. https://doi.org/10.1016/S0140-6736(11)61625-5 4. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983. https://doi.org/10.1200/JCO.2003.02.063 5. Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA (2012) Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14(4):R110. https://doi.org/10.1186/bcr3231
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|